Ameriprise’s Biocept, Inc. BIOC Stock Holding History

Ameriprise’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-387	Closed	-$3.94K	–	4051
2023 Q1	$3.94K	Sell	387 -22	-5%	-$318	﹤0.01%	3929
2022 Q4	$7K	Sell	409 -23	-5%	-$507	﹤0.01%	3941
2022 Q3	$12K	Sell	432 -6	-1%	-$178	﹤0.01%	3935
2022 Q2	$12K	Sell	438 -5,963	-93%	-$272K	﹤0.01%	3863
2022 Q1	$446K	Buy	6,401 +119	+2%	+$9.35K	﹤0.01%	3530
2021 Q4	$682K	Buy	6,282 +5,794	+1,187%	+$667K	﹤0.01%	3416
2021 Q3	$59K	Sell	488 -7	-1%	-$817	﹤0.01%	3810
2021 Q2	$62K	Sell	495 -14	-3%	-$1.9K	﹤0.01%	3849
2021 Q1	$78K	Sell	509 -10	-2%	-$1.82K	﹤0.01%	3790
2020 Q4	$69K	Sell	519 -8	-2%	-$1.14K	﹤0.01%	3711
2020 Q3	$70K	Buy	+527	New	+$106K	﹤0.01%	3665
2019 Q4	–	Sell	-33	Closed	-$8K	–	3782
2019 Q3	$8K	Sell	33 -34	-51%	-$9.79K	﹤0.01%	3699
2019 Q2	$22K	Hold	67	–	–	﹤0.01%	3702
2019 Q1	$23K	Buy	+67	New	+$27.1K	﹤0.01%	3668

Other funds holding BIOC

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ameriprise's BIOC Position: Q2 2023 in Review

Ameriprise sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 387 shares — an estimated $3.94K sold.

Ameriprise first reported a position in BIOC in Q1 2019 and held it in 14 quarters. The position peaked at $682K in Q4 2021. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

Ameriprise reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
Ameriprise sold 387 Biocept, Inc. shares in Q2 2023, an estimated $3.94K.
Ameriprise first reported a position in Biocept, Inc. in Q1 2019 and held it in 14 quarters.
Ameriprise's Biocept, Inc. position peaked at $682K in Q4 2021.
11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.